Unraveling nuanced roles of JAK inhibitors in inflammation

Researchers at the Icahn School of Medicine at Mount Sinai have gained a deeper understanding of the nuanced roles of JAK inhibitors, or modulators, in inflammation across various cell types and tissues.

Landmark CRISPR approval; Why don’t investors like Verve’s base editing data?; Janet Woodcock to retire; Late Friday IPO filing; and more

Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday morning? Current Endpoints readers can visit

November 19, 2023

The evolving nature of infant-caregiver communication

Compared to other mammals, human children are dependent on their caregivers for a remarkably long time. Throughout the ages, they have developed “psychological tactics” to

August 7, 2024

Lilly’s Retevmo lands new accelerated approval for pediatric cancers

Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS

May 30, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.